KLK3 and prostate cancer: Thus, future plans for adaptive therapy trials in prostate cancer include more rapid withdrawal of therapy when PSA crosses the 50% threshold and more extensive monitoring of intratumoral evolution using serum biomarkers, including testosterone as well as circulating DNA for AR amplification, AR mutations, and CYP17a expression.